Welcome to our dedicated page for Axogen SEC filings (Ticker: AXGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Whether you’re tracking the next clinical-trial milestone or comparing sales of the Avance Nerve Graft quarter over quarter, Axogen’s SEC documents hold the answers. Investors often ask, “Where can I find Axogen quarterly earnings report 10-Q filing?” or “How do I follow Axogen insider trading Form 4 transactions in real time?”—this page brings everything together.
Stock Titan’s platform delivers AI-powered summaries that turn dense disclosures into clear insights. Our engine flags key metrics—nerve-repair product revenue, R&D spend on regenerative medicine, FDA submissions—and explains them in plain English. Need a quick read of an Axogen annual report 10-K simplified? Interested in understanding Axogen SEC documents with AI before the market opens? Each filing appears here moments after it hits EDGAR, complete with contextual charts and peer comparisons.
- Set alerts for Axogen Form 4 insider transactions real-time to monitor executive stock transactions Form 4.
- Drill into Axogen 8-K material events explained, such as clinical data releases or supply-chain updates.
- Review the Axogen proxy statement executive compensation to see how surgeon-education incentives align with shareholder value.
Because Axogen operates in the highly regulated medical-device arena, each filing carries details on tissue-processing standards, reimbursement risk, and hospital adoption curves—information often buried in footnotes. Our AI surfaces those specifics so you can focus on decisions, not document hunting. Bookmark this hub whenever you need Axogen SEC filings explained simply, from Axogen earnings report filing analysis to the smallest change in risk factors.
Axogen (AXGN) reported Q3 2025 results. Revenue was $60,082, up 23.5% year over year, with gross profit of $45,993 and gross margin of 76.6%. The quarter delivered net income of $708 (diluted EPS $0.01) versus a loss a year ago, as sales and marketing investments supported higher volumes and pricing.
For the first nine months, revenue reached $165,304 and net loss was $2,547. Cash, cash equivalents and investments totaled $35,791 as of September 30, 2025. Management noted that discontinuing the Avance case stock program and moving some customers to direct orders increased Q3 revenue by about $1.6 million.
Industry tailwinds included new society statements from AAHS and ASRM recognizing nerve allograft as a standard option and broader payer coverage, adding approximately 18.1 million covered lives in 2025. The FDA accepted the BLA for Avance Nerve Graft and, after a major amendment, set a December 5, 2025 PDUFA goal date.
Axogen, Inc. furnished an 8-K announcing its third quarter 2025 financial results communications. The company issued a Q3 2025 earnings press release and posted a results presentation; these are furnished under Items 2.02 and 7.01, respectively.
The materials are available as Exhibit 99.1 (press release) and Exhibit 99.2 (presentation) dated October 29, 2025, and are furnished rather than filed. The presentation was also posted at https://ir.axogeninc.com/news-events.
Axogen, Inc. (AXGN): Form 4 insider transaction — A company director reported a sale of common stock on 10/22/2025. The filing shows 1,457 shares were sold at a weighted average price of $18.018 per share, with individual trades executed between $18.00 and $18.045.
The transaction was made pursuant to a Rule 10b5-1(c) trading plan adopted on March 14, 2025. Following the sale, the reporting person beneficially owns 100 shares directly.
Axogen, Inc. (AXGN) director William P. Burke reported the sale of 736 shares of common stock on
William P. Burke, a director of Axogen, Inc. (AXGN), reported multiple sales of common stock on
The Form 4 states the transactions were made pursuant to a Rule 10b5-1(c) trading plan adopted March 14, 2025. After the reported transactions the schedule shows 2,293 shares held directly and 0 shares held indirectly by the trust in the most recent line, reflecting the post-transaction beneficial ownership reported on the form.
Axogen, Inc. (AXGN) submitted a Form 144 notice reporting a proposed sale of 736 common shares through Fidelity Brokerage Services LLC with an aggregate market value of $13,248.80 and an approximate sale date of 10/06/2025 on NASDAQ. The filer reports the shares were acquired in an open market purchase on 08/24/2023 and fully paid in cash.
The filing also discloses multiple recent sales by related parties within the prior days: four transactions on 10/02/2025 and 10/03/2025 totaling 36,264 shares with combined gross proceeds shown. The filing includes standard attestations about material nonpublic information and Rule 10b5-1 trading-plan references but provides no additional commentary or financial results.
Axogen, Inc. insider filing shows a proposed sale of 14,937 common shares, with an aggregate market value of $267,073.56, through Morgan Stanley Smith Barney LLC on 10/03/2025. The shares were acquired as Restricted Stock Units on 09/01/2024. The filer declares no undisclosed material information and notes reliance on Rule 144 and any applicable 10b5-1 trading plan mechanics. The notice also reports recent sales on 10/02/2025 totaling 10,020 shares for gross proceeds of $180,424.04 executed under a 10b5-1 program and an irrevocable trust.
Axogen, Inc. (AXGN) filed a Form 144 notice reporting a proposed open-market sale of 11,307 common shares with an aggregate market value of $206,316.82. The filing lists the broker as Fidelity Brokerage Services LLC and indicates the shares are to be sold on NASDAQ with an approximate sale date of 10/03/2025. The securities were acquired in two open-market purchases on 08/23/2023 (7,600 shares) and 08/24/2023 (3,707 shares), paid in cash. The filing also discloses a prior sale on 10/02/2025 of 2,400 shares by the Elizabeth J Burke 2024 Irrevocable Trust for gross proceeds of $43,224.00. The filer affirms they are not aware of undisclosed material adverse information.
Axogen, Inc. (AXGN) filed a Form 144 reporting a proposed sale of 2,400 common shares through Fidelity Brokerage Services LLC on 10/02/2025 on the NASDAQ. The filing lists the aggregate market value of the shares as $43,224.00 and reports 46,012,574 shares outstanding. The shares were originally acquired in an open market purchase on 08/23/2023 and paid in cash on that date. The filer reports no securities sold in the past three months and includes the standard representation that the selling person does not possess undisclosed material information about the issuer.
Axogen, Inc. insider filed a Form 144 notifying a proposed sale of 7,620 shares of common stock through Morgan Stanley Smith Barney LLC with an aggregate market value of $136,169.40. The filing lists the number of shares outstanding as 46,012,574 and an approximate sale date of 10/02/2025 on NASDAQ. The securities were acquired as Restricted Stock Units on 09/01/2024 from the issuer and the filing reports "Nothing to Report" for sales in the prior three months. The Form 144 includes the standard signature representation that the seller is not aware of undisclosed material adverse information.
FAQ
What is the current stock price of Axogen (AXGN)?
What is the market cap of Axogen (AXGN)?
